Back to Search Start Over

In fresh blow to floundering PI3K space, FDA feedback drives MEI, Kyowa to halt blood cancer program.

Authors :
Taylor, Nick Paul
Source :
FierceBiotech; 12/6/2022, pN.PAG-N.PAG, 1p
Publication Year :
2022

Abstract

After meeting with the FDA, Kyowa Kirin and MEI Pharma have stopped development of their B-cell malignancy prospect zandelisib outside of Japan. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
PHOSPHATIDYLINOSITOL 3-kinases
B cells
NON-Hodgkin's lymphoma

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
160646020

Tools

Authors Abstract Subjects Details